Artiva Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
| THREE MONTHS ENDED SEPTEMBER 30, | NINE MONTHS ENDED SEPTEMBER 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue: | ||||
| Collaboration revenue | $— | $26,656 | $— | $31,142 |
| License and development support revenue (including related party amounts of $0, $0, $251 and $0, respectively) | — | — | 251 | — |
| Total revenue | — | 26,656 | 251 | 31,142 |
| Operating expenses: | ||||
| Research and development (including related party amounts of $1,342, $1,525, $2,802 and $3,335, respectively) | 13,524 | 13,065 | 37,011 | 39,098 |
| General and administrative | 4,811 | 2,780 | 12,255 | 10,745 |
| Total operating expenses | 18,335 | 15,845 | 49,266 | 49,843 |
| Income (loss) from operations | (18,335) | 10,811 | (49,015) | (18,701) |
| Other income (expense), net: | ||||
| Interest income | 1,846 | 418 | 3,172 | 1,952 |
| Change in fair value of SAFEs (including related party amounts of $799, $0, $2,911 and $0, respectively) | (977) | — | (3,597) | — |
| Other income (expense), net | (6) | 50 | 162 | 27 |
| Total other income (expense), net | 863 | 468 | (263) | 1,979 |
| Net income (loss) | $(17,472) | $11,279 | $(49,278) | $(16,722) |
| Net income (loss) per share: | ||||
| Basic | $(0.92) | $13.98 | $(7.16) | $(20.89) |
| Diluted | $(0.92) | $1.62 | $(7.16) | $(20.89) |
| Weighted-average common shares outstanding: | ||||
| Basic | 18,896,829 | 806,714 | 6,883,271 | 800,541 |
| Diluted | 18,896,829 | 6,967,099 | 6,883,271 | 800,541 |
| Comprehensive income (loss): | ||||
| Net income (loss) | $(17,472) | $11,279 | $(49,278) | $(16,722) |
| Other comprehensive income: | ||||
| Unrealized gain on investments | 217 | 144 | 30 | 271 |
| Comprehensive income (loss) | $(17,255) | $11,423 | $(49,248) | $(16,451) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.